Literature DB >> 19408964

Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans.

Grover P Miller1, Drew R Jones, Shane Z Sullivan, Anna Mazur, Suzanne N Owen, Neil C Mitchell, Anna Radominska-Pandya, Jeffery H Moran.   

Abstract

As a step toward exploring a targeted metabolomics approach to personalized warfarin (Coumadin) therapy, we developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method capable of quantifying specific enantiomeric (R and S) contributions of warfarin (WAR) and the corresponding hydroxywarfarins (OH-WAR) and glucuronides (-GLUC) generated by cytochrome P450s (CYP) and UDP-glucuronosyltransferases (UGTs), respectively. Evaluation of quality control samples and three commercially available human samples showed that our analytical approach has the ability to measure 24 unique WAR metabolites in human urine. Evaluation of the human data also provides new insights for evaluating WAR toxicity and begins characterizing important UGT metabolic pathways responsible for WAR detoxification. Data revealed the significance of specific metabolites among patients and the corresponding enzymatic capacity to generate these compounds, including the first report of direct WAR glucuronidation. On the basis of total OH-WAR levels, (S)-7-OH-WAR was the predominant metabolite indicating the significance of CYP2C9 in WAR metabolism, although other CYP2C enzymes also contributed to clearance of this isomer. (R)-WAR hydroxylation to OH-WARs was more diverse among the patients as reflected in varying contributions of CYP1A2 and multiple CYP2C enzymes. There was wide variation in the glucuronidation of WAR and the OH-WARs with respect to the compounds and patients. 6- and 7-OH-WAR were primarily (>70%) excreted as glucuronides unlike 4'-OH-WAR and 8-OH-WAR. For all patients, UGT1A1 is likely responsible for 6-O-GLUC production, although UGT1A10 may also contribute in one patient. 7-O-GLUC levels reflected contributions from potentially five different UGT1A enzymes. In all cases, WAR, 4'-OH-WAR, 8-OH-WAR, and the corresponding glucuronides were minor metabolites with respect to the others. Taken together, these data suggest that both P450 and UGT reactions contribute to the generation of excretable products in human urine, thereby generating complex metabolic networks.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19408964      PMCID: PMC2819755          DOI: 10.1021/tx900031z

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  17 in total

Review 1.  Pharmacogenomics of 4-hydroxycoumarin anticoagulants.

Authors:  Nicholas Au; Allan E Rettie
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

2.  Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.

Authors:  L C Wienkers; C J Wurden; E Storch; K L Kunze; A E Rettie; W F Trager
Journal:  Drug Metab Dispos       Date:  1996-05       Impact factor: 3.922

Review 3.  Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions.

Authors:  J K Ritter
Journal:  Chem Biol Interact       Date:  2000-12-01       Impact factor: 5.192

4.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.

Authors:  A E Rettie; K R Korzekwa; K L Kunze; R F Lawrence; A C Eddy; T Aoyama; H V Gelboin; F J Gonzalez; W F Trager
Journal:  Chem Res Toxicol       Date:  1992 Jan-Feb       Impact factor: 3.739

5.  A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

Authors:  Gregory M Cooper; Julie A Johnson; Taimour Y Langaee; Hua Feng; Ian B Stanaway; Ute I Schwarz; Marylyn D Ritchie; C Michael Stein; Dan M Roden; Joshua D Smith; David L Veenstra; Allan E Rettie; Mark J Rieder
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

6.  Metabolism of vitamin K and vitamin K 2,3-epoxide via interaction with a common disulfide.

Authors:  J J Lee; M J Fasco
Journal:  Biochemistry       Date:  1984-05-08       Impact factor: 3.162

7.  Phase II metabolism of warfarin in primary culture of adult rat hepatocytes.

Authors:  R L Jansing; E S Chao; L S Kaminsky
Journal:  Mol Pharmacol       Date:  1992-01       Impact factor: 4.436

8.  Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe.

Authors:  Z Zhang; M J Fasco; Z Huang; F P Guengerich; L S Kaminsky
Journal:  Drug Metab Dispos       Date:  1995-12       Impact factor: 3.922

9.  Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe.

Authors:  L S Kaminsky; S M de Morais; M B Faletto; D A Dunbar; J A Goldstein
Journal:  Mol Pharmacol       Date:  1993-02       Impact factor: 4.436

10.  Identification of hydroxywarfarin binding site in human UDP glucuronosyltransferase 1a10: phenylalanine90 is crucial for the glucuronidation of 6- and 7-hydroxywarfarin but not 8-hydroxywarfarin.

Authors:  Grover P Miller; Cheryl F Lichti; Agnieszka K Zielinska; Anna Mazur; Stacie M Bratton; Anna Gallus-Zawada; Moshe Finel; Jeffery H Moran; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2008-08-25       Impact factor: 3.922

View more
  11 in total

1.  Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

Authors:  Drew R Jones; So-Young Kim; Michael Guderyon; Chul-Ho Yun; Jeffery H Moran; Grover P Miller
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

2.  Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.

Authors:  C Preston Pugh; Dakota L Pouncey; Jessica H Hartman; Robert Nshimiyimana; Linda P Desrochers; Thomas E Goodwin; Gunnar Boysen; Grover P Miller
Journal:  Arch Biochem Biophys       Date:  2014-10-19       Impact factor: 4.013

3.  Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferases.

Authors:  Stacie M Bratton; Carrie M Mosher; Farid Khallouki; Moshe Finel; Michael H Court; Jeffery H Moran; Anna Radominska-Pandya
Journal:  J Pharmacol Exp Ther       Date:  2011-10-04       Impact factor: 4.030

4.  Pharmacokinetic Modeling of Warfarin ІI - Model-based Analysis of Warfarin Metabolites following Warfarin Administered either Alone or Together with Fluconazole or Rifampin.

Authors:  Shen Cheng; Darcy R Flora; Allan E Rettie; Richard C Brundage; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2022-07-07       Impact factor: 3.579

5.  Pharmacokinetic Modeling of Warfarin І - Model-based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-dependent Drug-drug Interactions of S-Warfarin.

Authors:  Shen Cheng; Darcy R Flora; Allan E Rettie; Richard C Brundage; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2022-07-07       Impact factor: 3.579

6.  Simultaneous Characterization and Determination of Warfarin and Its Hydroxylation Metabolites in Rat Plasma by Chiral Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Shasha Jin; Zhihong Li; Qing Yang; Boyu Fang; Xiaoqiang Xiang; Chao Peng; Weimin Cai
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

7.  Development of a chiral micellar electrokinetic chromatography-tandem mass spectrometry assay for simultaneous analysis of warfarin and hydroxywarfarin metabolites: application to the analysis of patients serum samples.

Authors:  Xiaochun Wang; Jingguo Hou; Michael Jann; Yuen Yi Hon; Shahab A Shamsi
Journal:  J Chromatogr A       Date:  2012-11-26       Impact factor: 4.759

8.  Validation and Application of a Simple UHPLC-MS-MS Method for the Enantiospecific Determination of Warfarin in Human Urine.

Authors:  Osama Y Alshogran; Andrew J Ocque; François A Leblond; Vincent Pichette; Thomas D Nolin
Journal:  J Chromatogr Sci       Date:  2015-12-11       Impact factor: 1.618

9.  Metabolic profiling of HepG2 cells incubated with S(-) and R(+) enantiomers of anti-coagulating drug warfarin.

Authors:  Jing Bai; Ming Xuan Wang; Balram Chowbay; Chi Bun Ching; Wei Ning Chen
Journal:  Metabolomics       Date:  2010-11-25       Impact factor: 4.290

10.  Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin.

Authors:  Dakota L Pouncey; Dustyn A Barnette; Riley W Sinnott; Sarah J Phillips; Noah R Flynn; Howard P Hendrickson; S Joshua Swamidass; Grover P Miller
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.